Rays of Belief Q1 Profit at Rs 2.79 Crore Post-Listing

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Rays of Belief Q1 Profit at Rs 2.79 Crore Post-Listing

Rays of Belief Limited posted a strong Q1 FY27 performance, reporting a net profit of Rs 2.79 crore against a loss in the previous year. Revenue surged to Rs 25.31 crore, driven by a balanced contribution from India and the US. Following its September 2026 listing, the company has also expanded its footprint by acquiring City Pro Group Inc. via its US subsidiary.

Rays of Belief Q1 Profit Hits Rs 2.79 Crore

Revenue rose to Rs 25.31 crore, while net profit transitioned to Rs 2.79 crore.

Reader Takeaway: Strong revenue growth and pivot to profit are positive, though US integration risks remain for investors.

What just happened

Rays of Belief Limited announced its financial results for the quarter ended June 30, 2026, marking its first report following its September 2026 listing. The company reported a net profit of Rs 2.79 crore, a sharp turnaround from the Rs 0.54 crore net loss recorded in the same period last year. Revenue saw significant momentum, reaching Rs 25.31 crore compared to Rs 10.71 crore in the year-ago period.

Why this matters

The results highlight the company's scaling operations in the neurodevelopmental therapy sector. A key driver for this performance is the near-equal split in revenue contribution between its India operations (49.34%) and its US operations (50.66%). The transition to profitability suggests improved operational efficiency following the scale-up.

Strategic Update

On September 18, 2026, the company's subsidiary, Mom’s Belief US Inc., acquired 100% of City Pro Group Inc. This makes City Pro Group a step-down subsidiary. This inorganic growth move is intended to bolster the company's presence in the US market, which is a significant contributor to its total revenue.

What to track next

Investors should monitor the integration of City Pro Group Inc. into the existing business model. The ability of the company to maintain consistent profit margins while managing cross-border operations and therapy service delivery across diverse geographies will be the primary performance indicator in upcoming quarters.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.